The vast majority of parents, 82.7 percent, reported being «somewhat» (36 percent), «very» (28 percent), or «extremely» (18 percent) interested in
newborn genomic testing.
Not exact matches
Economic Modeling: Our economic modeling core, led by Dr. Ann Wu, uses a variety of modeling approaches to project the medical and financial consequences of
genomic medicine, including the use of pharmacogenomic
testing to inform medication choices and the use of sequencing as an adjunct to standard
newborn screening.
The BabySeq Project:
Genomic Sequencing for Childhood Risk and
Newborn Illness (U19 HD077671) is a first - of - its - kind randomized clinical trial designed to examine how best to use
genomics in clinical pediatric medicine by creating and safely
testing methods for integrating sequencing into the care of
newborns.
Topics at «Genetics — Moving to the Center of Healthcare» include the role of
genomic testing in guiding cancer treatment, approaches to helping families that are coping with genetic diagnoses, and interpretation and use of
genomic sequencing results in the
newborn population.